Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Omnibus appropriations

This article was originally published in The Gray Sheet

Executive Summary

Senate may reconvene in December to consider seven-bill spending package, which would dole out $209.4 mil. for CDRH in agriculture appropriations conference report provision. The House is scheduled to consider the legislation when it reconvenes during the week of Dec. 8; Senate options include funding FDA at FY 2003 levels under a continuing resolution through Jan. 31, 2004, or unanimous consent passage before year-end. The amount closely aligns with the Senate bill, passed Nov. 6 (1"The Gray Sheet" Nov. 10, 2003, In Brief)...

You may also be interested in...



Congress backs CDRH raise

Senate votes 93-1 to spend $209.3 mil. for device center in FY 2004 agriculture approps bill Nov. 6, including $29.2 mil. in user fees. The House-cleared report offers $193.5 mil. in CDRH budget authority, while the Senate report originally proposed $191.9 mil. (1"The Gray Sheet" Nov. 3, 2003, p. 5). In its request to reconcile the amounts, the Senate appointed 17 conferees...

IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf

Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.

UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026

Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT019441

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel